Teva Files Lawsuit Against Eli Lilly Over Patents for Migraine Drug

June 15, 2021

Teva Pharmaceuticals has filed a new patent infringement complaint against Eli Lilly over competing migraine drugs.

Teva’s latest suit in an ongoing battle with Eli Lilly came just hours after the U.S. Patent and Trademark Office issued two new patents on Teva’s migraine drug, Ajovy (fremanezumabin).

Teva had previously sued Lilly for alleged infringement on nine of Teva’s Ajovy patents, following the FDA’s approval of Lilly’s migraine drug, Emgality (galcanezumab-gnlm).

In the new complaint filed June 8 in the U.S. District Court for Massachusetts, the Israeli drugmaker says Emgality infringes upon the two newly granted Ajovy patents. The company is seeking to block Lilly from making and selling Emgality in the U.S. and is also seeking damages.

View today's stories